ASMB NASDAQ
Credit Risk of going bust: lower than 80% of companies Debt: 0.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.9%), Assembly Biosciences, Inc. would be worth roughly what it owes.
Total debt $2.4M against a stock market value of $400.5M.
Distance to default 9.66 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.2M (short-term plus half of long-term), stock volatility 59.2%; Altman Z'' 10.46. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
South San Francisco, CA 94080
US
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bjorkquist Jeanette | S-Sale | 29 | $23.25 | 2026-06-17 |
| ALTIG ANTHONY E | A-Award | 8,000 | $24.11 | 2026-06-04 |
| Johnson-Pratt Lisa | A-Award | 8,000 | $24.11 | 2026-06-04 |
| Houghton Michael | A-Award | 8,000 | $24.11 | 2026-06-04 |
| Consylman Gina | A-Award | 8,000 | $24.11 | 2026-06-04 |